Net price increases for seven drugs raised U.S. drug spending by $5.1 billion between 2017 and 2018 without evidence of improved safety or effectiveness, according to the first annual report by the Institute for Clinical and Economic Review on the costliest U.S. drug price increases unsupported by clinical evidence. For example, the average U.S. price for Humira, a drug used to treat chronic illnesses such as rheumatoid arthritis, increased 15.9% over the period after accounting for rebates and other concessions, raising spending on the drug by an additional $1.86 billion. “If new evidence emerges that shows a treatment may be more beneficial than what was previously understood, perhaps that new evidence could warrant some level of price increase,” said David Rind, M.D., chief medical officer for the independent research institute. “For seven of the nine drugs we reviewed, however, we found that the price increases lacked justification in new evidence.”

Related News Articles

Nearly 50 health care and consumer groups, including the AHA, voiced their support for the Creating and Restoring Equal Access to Equivalent Samples Act as it…
The Senate Health, Education, Labor & Pensions Committee today held a hearing to examine how primary care affects health care costs and outcomes.
The Department of Health and Human Services’ Office of Inspector General yesterday proposed excluding from safe harbor protection under the Anti-Kickback…
The Senate Finance Committee today held the first in a planned series of bipartisan hearings on high prescription drug prices and potential policy and…
Insights and Analysis
Also in this weekly roundup of health care related news: Cleveland Clinic leader discusses health care trends, and how one health system uses real-time data to…
Last week, I shared a few areas where we can advance health in America this year, even in a divided Congress.